Inhibitory activity of garenoxacin against DNA gyrase of Mycoplasma pneumoniae

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 8, 2012, Pages 1850-1852

  Nakatani, Masatoshi ^a   Mizunaga, Shingo ^a   Takahata, Masahiro ^a   Nomura, Nobuhiko ^a  

^a TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

Purification; Quinolones; Recombinant proteins; Supercoiling activity

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; GARENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; ESCHERICHIA COLI; IC 50; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA PNEUMONIAE; NONHUMAN; PLASMID; PROTEIN EXPRESSION;

ANTI-BACTERIAL AGENTS; DNA GYRASE; ENZYME INHIBITORS; ESCHERICHIA COLI; FLUOROQUINOLONES; GENE EXPRESSION; INHIBITORY CONCENTRATION 50; MYCOPLASMA PNEUMONIAE; PLASMIDS; PROTEIN SUBUNITS; QUINOLONES; RECOMBINANT PROTEINS;

EID: 84864500806     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks140     Document Type: Article

References (10)

1. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004; 17: 697-728.
2. Peuchant O, Ménard A, Renaudin H et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009; 64: 52-8.
3. Morozumi M, Iwata S, Hasegawa K et al. Increased macrolide resistance ofMycoplasmapneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother 2008; 52: 348-50.
4. Lin Y, Ye X, Zhang H et al. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Antimicrob Agents Chemother 2010; 67: 355-8.
5. Chironna M, Sallustio A, Esposito S et al. Emergence ofmacrolide-resistant strains during an outbreakofMycoplasmapneumoniae infections in children. J Antimicrob Chemother 2011; 66: 734-7.
6. Yamazaki T, Sasaki T, Takahata M. Activity of garenoxacin against macrolide-susceptible and -resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother 2007; 51: 2278-9.
7. Gellert M. DNA topoisomerases. Annu Rev Biochem 1981; 50: 879-910.
8. Tanaka M, Onodera Y, Uchida Y et al. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41: 2362-6.
9. Pan XS, Fisher LM. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones. Antimicrob Agents Chemother 1999; 43: 1129-36.
10. Ince D, Zhang X, Silver LC et al. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob Agents Chemother 2002; 46: 3370-80.